Man Group’s Mustang Bio MBIO Stock Holding History

Man Group’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Hold	0	–	–	–	2017
2021 Q2	–	Sell	-90	Closed	-$223K	–	2036
2021 Q1	$223K	Buy	+90	New	+$268K	﹤0.01%	1723

Other funds holding MBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Man Group's MBIO Position: Q2 2022 in Review

Man Group held its Mustang Bio (MBIO) position steady in Q2 2022 at 0 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Man Group first reported a position in MBIO in Q1 2021 and has held it in 1 quarter since. The position peaked at $223K in Q1 2021. 71 funds tracked by Wall St. Rank hold MBIO as of Q2 2022.

Man Group held 0 shares of Mustang Bio worth $6K as of Q2 2022.
Man Group left its Mustang Bio share count unchanged in Q2 2022.
Mustang Bio made up ﹤0.01% of Man Group's portfolio in Q2 2022, its #2017 holding.
Man Group first reported a position in Mustang Bio in Q1 2021 and has held it in 1 quarter since.
Man Group's Mustang Bio position peaked at $223K in Q1 2021.
71 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.